Deadline: 7-Apr-25
Pfizer is offering its funding to support personalized treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Area of Interest
- General Area of Interest for this RFP: Projects that will be considered for Pfizer support will focus on increasing healthcare professional awareness and knowledge in the following five (5) areas:
- Personalized treatment in mCRPC: Understanding the rationale for PARP inhibitor combinations (including the MOA, latest clinical data, treatment sequencing) and identifying the optimal patient for PARP inhibitor therapy in mCRPC. Tools for patient counselling and shared decision making are also of interest.
- Improved genetic and biomarker testing: Foster best practices in ordering, interpreting, and applying genetic and biomarker test results in clinical practice. Understand and explain the impact to patients (including germline and somatic testing and implementing reflex/mainstream testing). Increase awareness of the Canadian Urological Association (CUA) genetic testing guidelines for prostate cancer.
- Enhanced multidisciplinary collaboration in clinical practice: Promote integration of care and communication between multidisciplinary team members managing mCRPC, including specialists (e.g. medical oncologists, urologists, uro-oncologists, radiation oncologists, pathologists) and health professionals (e.g. nurses, nurse practitioners, general practitioners in oncology (GPOs), pharmacists, genetic counsellors).
- Management of PARP inhibitor therapy and side effects: Education on initiating treatment and preventing, monitoring, and managing side effects; including the role of patient counselling and of multi-disciplinary team members to optimize patient outcomes.
- Expand education for community and rural HCPs involved in treating mCRPC: Tailor education to integrate the latest data and treatment advancements based on the unmet needs specific to treatment setting; connect community HCPs with specialists in their regions and foster collaboration between academic and community centers.
Funding Information
- Individual projects requesting up to $100,000 (CAD) will be considered. The estimated total available budget related to this RFP is $200,000 (CAD).
Format
- Examples of educational formats that will be considered under this RFP include but are not limited to:
- Peer-to-peer education
- On-agenda educational sessions during live conferences
- Satellite symposia
- Expert interviews recorded at live conferences, conference coverage reviews
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations
Target Audience
- Academic and community medical oncologists, urologists, uro-oncologists, oncology nurses and nurse practitioners, radiation oncologists, pharmacists, genetic counsellors, pathologists, and other healthcare professionals involved in the care and treatment of patients with mCRPC cancer.
Eligibility Criteria
- Geographic Scope/Location of Project: Canada
- Applicant Eligibility Criteria
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
For more information, visit Pfizer.
